Multiscale distribution and bioaccumulation analysis of clofazimine reveals a massive immune system-mediated xenobiotic sequestration response

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 3, 2013, Pages 1218-1230

  Baik, Jason ^b   Stringer, Kathleen A ^a   Mane, Gerta ^a   Rosania, Gus R ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFAZIMINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; XENOBIOTIC AGENT;

ACUTE PHASE RESPONSE; ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EXPOSURE; DRUG TISSUE LEVEL; IMMUNE RESPONSE; LIVER CELL; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SPLEEN CELL;

ACUTE-PHASE REACTION; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLOFAZIMINE; CYTOKINES; IMMUNE SYSTEM; LIVER; MACROPHAGES; MALE; MICE; MICE, INBRED BALB C; RECEPTORS, INTERLEUKIN-1; SPLEEN; XENOBIOTICS;

EID: 84874046848     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01731-12     Document Type: Article

References (56)

1. Banerjee DK, Ellard GA, Gammon PT, Waters MF. 1974. Some observations on the pharmacology of clofazimine (B663). Am. J. Trop. Med. Hyg. 23:1110 -1115.
2. Queiroz RHC, de Souza AM, Sampaio SV, Melchior E. 2002. Biochemical and hematological side effects of clofazimine in leprosy patients. Pharmacol. Res. 46:191-194.
3. Cholo MC, Steel HC, Fourie PB, Germishuizen WA, Anderson R. 2011. Clofazimine: current status and future prospects. J. Antimicrob. Chemother. 67:290 -298.
4. O'Connor R, O'Sullivan JF, O'Kennedy R. 1995. The pharmacology, metabolism, and chemistry of clofazimine. Drug Metab. Rev. 27:591- 614.
5. Mansfield RE. 1974. Tissue concentrations of clofazimine (B663) in man. Am. J. Trop. Med. Hyg. 23:1116 -1119.
6. Venkatesan K, Deo N, Gupta UD. 2007. Tissue distribution and deposition of clofazimine in mice following oral administration with or without isoniazid. Arzneimittelforschung 57:472- 474.
7. Greenwood D. 2008. Antimicrobial drugs: chronicle of a twentieth century medical triumph. Oxford University Press, Oxford, England.
8. Barry VC, Buggle K, Byrne J, Conalty ML, Winder F. 1960. Absorption, distribution and retention of the riminocompounds in the experimental animal. Ir. J. Med. Sci. 416:345-352.
9. McDougall AC, Horsfall WR, Hede JE, Chaplin AJ. 1980. Splenic infarction and tissue accumulation of crystals associated with the use of clofazimine (Lamprene; B663) in the treatment of pyoderma gangrenosum. Br. J. Dermatol. 102:227-230.
10. Dey T, Brigden G, Cox H, Shubber Z, Cooke G, Ford N. 2012. Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. J. Antimicrob. Chemother. doi:10 .1093/jac/dks389.
11. Levy L, Randall H. 1970. A study of skin pigmentation by clofazimine. Int. J. Lepr. Other Mycobact. Dis. 38:404-416.
12. Aplin RT, McDougall AC. 1975. Identification of crystals of the riminophenazine compound B663 (Lamprene: clofazimine) in mouse spleen macrophages by thin layer chromatography and mass spectrum analysis. Experientia 31:468-469.
13. Baik J, Rosania GR. 2012. Macrophages sequester clofazimine in an intracellular liquid crystal-like supramolecular organization. PLoS One 7:e47494. doi:10.1371/journal.pone.0047494.
14. McDougall AC. 1974. Electron microscope studies of the antileprosy drug B663 (clofazimine; Lamprene). Int. J. Lepr. Other Mycobact. Dis. 42:1-12.
15. Desikan KV, Ramanujam K, Ramu G, Balakrishnan S. 1975. Autopsy findings in a case of lepromatous leprosy treated with clofazimine. Lepr. Rev. 46:181-189.
16. Sukpanichnant S, Hargrove NS, Kachintorn U, Manatsathit S, Chanchairujira T, Siritanaratkul N, Akaraviputh T, Thakerngpol K. 2000. Clofazimine-induced crystal-storing histiocytosis producing chronic abdominal pain in a leprosy patient. Am. J. Surg. Pathol. 24:129 -135.
17. Wan H, Holmen AG, Wang Y, Lindberg W, Englund M, Nagard MB, Thompson RA. 2003. High-throughput screening of pKa values of pharmaceuticals by pressure-assisted capillary electrophoresis and mass spectrometry. Rapid Commun. Mass Spectrom. 17:2639 -2648.
18. de Duve C, de Barsy T, Poole B, Trouet A, Tulkens P, Van Hoof F. 1974. Commentary: lysosomotropic agents. Biochem. Pharmacol. 23: 2495-2531.
19. Baik J, Rosania GR. 2011. Molecular imaging of intracellular drugmembrane aggregate formation. Mol. Pharm. 8:1742-1749.
20. Alakoskela JM, Vitovic P, Kinnunen PK. 2009. Screening for the drugphospholipid interaction: correlation to phospholipidosis. ChemMed- Chem 4:1224 -1251.
21. Reasor MJ, Hastings KL, Ulrich RG. 2006. Drug-induced phospholipidosis: issues and future directions. Expert Opin. Drug Safety 5:567-583.
22. Sarracent J, Finlay CM. 1982. The action of Clofazimine on the level of lysosomal enzymes of cultured macrophages. Clin. Exp. Immunol. 48: 261-267.
23. Sarracent J, Finlay CM. 1984. In vivo effect of clofazimine in the lysosomal enzyme level and immune complex phagocytosis of mouse peritoneal macrophages. Int. J. Lepr. Other Mycobact. Dis. 52:154 -158.
24. Levy L. 1974. Pharmacologic studies of clofazimine. Am. J. Trop. Med. Hyg. 23:1097-1109.
25. Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, Gautam B, Hassanali M. 2008. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 36:D901-D906.
26. Stringer KA, Freed BM, Dunn JS, Sayers S, Gustafson DL, Flores SC. 2004. Particulate phase cigarette smoke increases MnSOD, NQO1, and CINC-1 in rat lungs. Free Radic. Biol. Med. 37:1527-1533.
27. Storey JD, Tibshirani R. 2003. Statistical methods for identifying differentially expressed genes in DNA microarrays. Methods Mol. Biol. 224: 149-157.
28. Storey JD, Tibshirani R. 2003. Statistical significance for genomewide studies. Proc. Natl. Acad. Sci. U. S. A. 100:9440 -9445.
29. Barry VC, Belton JG, Conalty ML, Denneny JM, Edward DW, O'Sullivan JF, Twomey D, Winder F. 1957. A new series of phenazines (rimino-compounds) with high antituberculosis activity. Nature 179: 1013-1015.
30. Rhodin JA. 1975. An atlas of histology, vol 1. Oxford University Press, New York, NY.
31. Jenkins SJ, Ruckerl D, Cook PC, Jones LH, Finkelman FD, van Rooijen N, MacDonald AS, Allen JE. 2011. Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation. Science 332:1284 -1288.
32. Schreuder H, Tardif C, Trump-Kallmeyer S, Soffientini A, Sarubbi E, Akeson A, Bowlin T, Yanofsky S, Barrett RW. 1997. A new cytokinereceptor binding mode revealed by the crystal structure of the IL-1 receptor with an antagonist. Nature 386:194 -200.
33. Schiff MH. 2000. Role of interleukin 1 and interleukin 1 receptor antagonist in the mediation of rheumatoid arthritis. Ann. Rheum. Dis. 59(Suppl 1):i103-i108.
34. Hannum CH, Wilcox CJ, Arend WP, Joslin FG, Dripps DJ, Heimdal PL, Armes LG, Sommer A, Eisenberg SP, Thompson RC. 1990. Interleukin- 1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 343:336 -340.
35. Arend WP, Malyak M, Guthridge CJ, Gabay C. 1998. Interleukin-1 receptor antagonist: role in biology. Annu. Rev. Immunol. 16:27-55.
36. Xu LL, Warren MK, Rose WL, Gong W, Wang JM. 1996. Human recombinant monocyte chemotactic protein and other C-C chemokines bind and induce directional migration of dendritic cells in vitro. J. Leukoc. Biol. 60:365-371.
37. Oppenheim JJ, Zachariae CO, Mukaida N, Matsushima K. 1991. Properties of the novel proinflammatory supergene "intercrine" cytokine family. Annu. Rev. Immunol. 9:617- 648.
38. Bystry RS, Aluvihare V, Welch KA, Kallikourdis M, Betz AG. 2001. B cells and professional APCs recruit regulatory T cells via CCL4. Nat. Immunol. 2:1126 -1132.
39. Romagnani S. 2002. Cytokines and chemoattractants in allergic inflammation. Mol. Immunol. 38:881- 885.
40. Beutler B, Cerami A. 1989. The biology of cachectin/TNF-a primary mediator of the host response. Annu. Rev. Immunol. 7:625- 655.
41. Kuziel WA, Morgan SJ, Dawson TC, Griffin S, Smithies O, Ley K, Maeda N. 1997. Severe reduction in leukocyte adhesion and monocyte extravasation in mice deficient in CC chemokine receptor 2. Proc. Natl. Acad. Sci. U. S. A. 94:12053-12058.
42. Devalaraja RM, Nanney LB, Du J, Qian Q, Yu Y, Devalaraja MN, Richmond A. 2000. Delayed wound healing in CXCR2 knockout mice. J. Invest. Dermatol. 115:234 -244.
43. Smith DF, Galkina E, Ley K, Huo Y. 2005. GRO family chemokines are specialized for monocyte arrest from flow. Am. J. Physiol. Heart Circ. Physiol. 289:H1976-H1984.
44. Colonna M, Facchetti F. 2003. TREM-1 (triggering receptor expressed on myeloid cells): a new player in acute inflammatory responses. J. Infect. Dis. 187(Suppl 2):S397-S401.
45. Ford JW, McVicar DW. 2009. TREM and TREM-like receptors in inflammation and disease. Curr. Opin. Immunol. 21:38-46.
46. Balakrishnan S, Desikan KV, Ramu G. 1976. Quantitative estimation of clofazimine in tissue. Lepr. India 48:732-738.
47. Berthiaume EP, Medina C, Swanson JA. 1995. Molecular sizefractionation during endocytosis in macrophages. J. Cell Biol. 129:989- 998.
48. Griffis LC, Twerdok LE, Francke-Carroll S, Biles RW, Schroeder RE, Bolte H, Faust H, Hall WC, Rojko J. 2010. Comparative 90-day dietary study of paraffin wax in Fischer-344 and Sprague-Dawley rats. Food Chem. Toxicol. 48:363-372.
49. Backer R, Schwandt T, Greuter M, Oosting M, Jungerkes F, Tuting T, Boon L, O'Toole T, Kraal G, Limmer A, den Haan JM. 2010. Effective collaboration between marginal metallophilic macrophages and CD8- dendritic cells in the generation of cytotoxic T cells. Proc. Natl. Acad. Sci. U. S. A. 107:216 -221.
50. Leenen PJ, Radosevic K, Voerman JS, Salomon B, van Rooijen N, Klatzmann D, van Ewijk W. 1998. Heterogeneity of mouse spleen dendritic cells: in vivo phagocytic activity, expression of macrophage markers, and subpopulation turnover. J. Immunol. 160:2166 -2173.
51. Aichele P, Zinke J, Grode L, Schwendener RA, Kaufmann SH, Seiler P. 2003. Macrophages of the splenic marginal zone are essential for trapping of blood-borne particulate antigen but dispensable for induction of specific T cell responses. J. Immunol. 171:1148 -1155.
52. Dinarello CA. 2000. The role of the interleukin-1-receptor antagonist in blocking inflammation mediated by interleukin-1. N. Engl. J. Med. 343: 732-734.
53. Aksentijevich I, Masters SL, Ferguson PJ, Dancey P, Frenkel J, van Royen-Kerkhoff A, Laxer R, Tedgard U, Cowen EW, Pham TH, Booty M, Estes JD, Sandler NG, Plass N, Stone DL, Turner ML, Hill S, Butman JA, Schneider R, Babyn P, El-Shanti HI, Pope E, Barron K, Bing X, Laurence A, Lee CC, Chapelle D, Clarke GI, Ohson K, Nicholson M, Gadina M, Yang B, Korman BD, Gregersen PK, van Hagen PM, Hak AE, Huizing M, Rahman P, Douek DC, Remmers EF, Kastner DL, Goldbach-Mansky R. 2009. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N. Engl. J. Med. 360: 2426-2437.
54. Sahu A, Saha K, Banerjee NR, Sehgal VN, Jagga CR. 1991. Effect of anti-leprosy drugs on superoxide anion production by rat peritoneal macrophage with special reference to light exposed clofazimine. Int. J. Immunopharmacol. 13:419-428.
55. Van Rensburg CE, Van Staden AM, Anderson R. 1993. The riminophenazine agents clofazimine and B669 inhibit the proliferation of cancer cell lines in vitro by phospholipase A2-mediated oxidative and nonoxidative mechanisms. Cancer Res. 53:318 -323.
56. Fukutomi Y, Maeda Y, Makino M. 2011. Apoptosis-inducing activity of clofazimine in macrophages. Antimicrob. Agents Chemother. 55:4000- 4005.